Crossmark Global Holdings Inc. acquired a new position in shares of Haemonetics Corporation (NYSE:HAE) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 9,849 shares of the medical instruments supplier’s stock, valued at approximately $442,000.
Several other large investors have also recently made changes to their positions in HAE. HealthCor Management L.P. grew its holdings in shares of Haemonetics by 15.9% during the 2nd quarter. HealthCor Management L.P. now owns 1,854,872 shares of the medical instruments supplier’s stock worth $73,249,000 after purchasing an additional 254,872 shares in the last quarter. Wells Fargo & Company MN boosted its stake in Haemonetics by 9.3% in the 2nd quarter. Wells Fargo & Company MN now owns 2,788,122 shares of the medical instruments supplier’s stock valued at $110,104,000 after buying an additional 238,294 shares in the last quarter. Anchor Capital Advisors LLC boosted its stake in Haemonetics by 41.7% in the 2nd quarter. Anchor Capital Advisors LLC now owns 774,906 shares of the medical instruments supplier’s stock valued at $30,601,000 after buying an additional 227,941 shares in the last quarter. Arrowstreet Capital Limited Partnership acquired a new stake in Haemonetics in the 2nd quarter valued at $6,115,000. Finally, Ameriprise Financial Inc. boosted its stake in Haemonetics by 21.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 578,516 shares of the medical instruments supplier’s stock valued at $22,844,000 after buying an additional 102,950 shares in the last quarter.
Haemonetics Corporation (HAE) traded down $0.55 during mid-day trading on Thursday, hitting $56.56. The stock had a trading volume of 734,578 shares, compared to its average volume of 358,138. The company has a market capitalization of $3,029.65, a P/E ratio of 35.19, a P/E/G ratio of 4.31 and a beta of 0.99. Haemonetics Corporation has a 12 month low of $36.44 and a 12 month high of $58.99. The company has a current ratio of 2.17, a quick ratio of 1.51 and a debt-to-equity ratio of 0.22.
Haemonetics (NYSE:HAE) last released its earnings results on Tuesday, November 7th. The medical instruments supplier reported $0.48 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.07. The company had revenue of $225.40 million during the quarter, compared to the consensus estimate of $219.12 million. Haemonetics had a return on equity of 11.16% and a net margin of 0.50%. The firm’s quarterly revenue was up 2.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.38 earnings per share. analysts predict that Haemonetics Corporation will post 1.7 EPS for the current year.
HAE has been the topic of several recent analyst reports. Zacks Investment Research raised Haemonetics from a “hold” rating to a “buy” rating and set a $52.00 price target on the stock in a research note on Wednesday, October 25th. Morgan Stanley boosted their price target on Haemonetics from $43.00 to $51.00 and gave the company an “equal weight” rating in a research note on Thursday, November 9th. Barrington Research lifted their price objective on Haemonetics from $48.00 to $57.00 and gave the company an “outperform” rating in a research report on Wednesday, November 8th. Finally, Craig Hallum reiterated a “hold” rating and issued a $50.00 price objective (up previously from $40.00) on shares of Haemonetics in a research report on Wednesday, November 8th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $53.33.
In other news, Director Pedro P. Granadillo sold 7,118 shares of the company’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $57.06, for a total transaction of $406,153.08. Following the completion of the transaction, the director now directly owns 31,663 shares of the company’s stock, valued at $1,806,690.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Susan Bartlett Foote sold 16,926 shares of the company’s stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $54.19, for a total value of $917,219.94. Following the transaction, the director now directly owns 27,313 shares of the company’s stock, valued at $1,480,091.47. The disclosure for this sale can be found here. Insiders sold 47,368 shares of company stock valued at $2,602,393 in the last quarter. 1.20% of the stock is currently owned by corporate insiders.
WARNING: This report was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another site, it was illegally copied and reposted in violation of US and international trademark and copyright law. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2017/12/07/crossmark-global-holdings-inc-buys-new-stake-in-haemonetics-corporation-hae.html.
Haemonetics Company Profile
Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.
Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.